J&P Medi announced on the 24th that it will hold the "2024 J&P Medi Connect" on November 22 at the Grand Ballroom of The Plaza Hotel in Jung-gu, Seoul.
This year, J&P Medi has expanded its business areas based on the clinical trial data platform, Mable Clinical Cloud, to include investment, contract research organization (CRO) services, and commercialization consulting for pharmaceutical, bio, and medical device companies, thereby strengthening its position as a life sciences research, development, and commercialization (RDC) company. This event will bring together industry experts to share the latest trends, experiences, and insights at each stage of RDC based on these achievements.
The academic organizing committee for this event is chaired by Ilseop Lee, Director of the Future Medicine Research Institute at Bundang CHA Hospital, and includes key industry figures such as Dahee Lee, CEO of Seoul CRO, Hanlim Moon, CEO of Medirama, and Hyeongjin Jeong, Executive Director of Korea Janssen. Experts from various fields, including Kyunghwa Heo, CEO of the Korea Innovative Medicines Consortium (KIMCo), and Daeyoung Jeong, Senior Manager at Ligacymbio, will participate as speakers, engaging in presentations and panel discussions for in-depth deliberations.
Jwonho Jeong, CEO of J&P Medi, said, "The 2024 J&P Medi Connect, now in its third year, is expected to provide valuable insights to industry stakeholders by going beyond simple information exchange to deeply address practical strategies and the latest technologies in the RDC field. It will be an important platform to systematically present key challenges and solutions at each stage, promoting innovative development across the industry and creating new opportunities for collaboration."
This event is open not only to professionals in the pharmaceutical, bio, and medical device industries but also to anyone interested in related fields. Information about the event and pre-registration can be found on the event website.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
